Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Abeona Therapeutics Inc (ABEO) Insider Trading Activity

    Healthcare • Biotechnology • 84 employees

    Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

    Total Value

    -$143,643.31

    Total Shares

    1,055,629

    Average Trade Value

    -$5,985.14

    Most Active Insider

    Seshadri Vishwas

    Total Activity: $122,362

    Largest Single Transaction

    $110,720

    by Seshadri Vishwas on Sep 28, 2024

    30-Day Activity

    13 Transactions

    Volume: 1,017,359 shares
    Value: $8,080

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Director
    Jan 31, 2025 36,101 $0 180,466 (+20.0%) Grant
    Director
    Jan 31, 2025 36,101 $0 47,145 (+76.6%) Grant
    Director
    Jan 31, 2025 36,101 $0 149,832 (+24.1%) Grant
    Director
    Jan 31, 2025 36,101 $10,000 47,145 (+76.6%) Grant
    Director
    Jan 31, 2025 36,101 $0 154,366 (+23.4%) Grant
    Director
    Jan 31, 2025 36,101 $0 150,612 (+24.0%) Grant
    Director
    Jan 31, 2025 36,101 $10,000 133,572 (+27.0%) Grant
    Director
    Jan 31, 2025 36,101 $0 100,435 (+35.9%) Grant
    Director
    Jan 29, 2025 4,000 $21,520 64,334 (-6.2%) Sale
    Chief Financial Officer
    Officer
    Jan 21, 2025 144,509 $10,000 509,726 (+28.4%) Grant
    Director
    Jan 21, 2025 4,000 $20,400 68,334 (-5.9%) Sale
    Svp, General Counsel
    Officer
    Jan 21, 2025 115,607 $10,000 388,896 (+29.7%) Grant
    Chief Executive Officer
    Director, Officer
    Jan 21, 2025 476,435 $10,000 1,380,322 (+34.5%) Grant
    Chief Executive Officer
    Director, Officer
    Oct 16, 2024 251 $1,642 903,887 (-0.0%) Payment of Exercise Price
    Chief Executive Officer
    Director, Officer
    Sep 28, 2024 18,798 $110,720 904,138 (-2.1%) Payment of Exercise Price
    Chief Financial Officer
    Officer
    Sep 28, 2024 6,388 $37,625 365,217 (-1.7%) Payment of Exercise Price
    Svp, General Counsel
    Officer
    Sep 28, 2024 6,579 $38,750 273,289 (-2.4%) Payment of Exercise Price
    Svp, General Counsel
    Officer
    Sep 20, 2024 496 $2,986 279,868 (-0.2%) Payment of Exercise Price
    Director
    Aug 26, 2024 11,797 $10,000 118,265 (+10.0%) Grant
    Director
    Aug 26, 2024 11,797 $10,000 114,511 (+10.3%) Grant
    Director
    Aug 26, 2024 11,797 $10,000 113,731 (+10.4%) Grant
    Director
    Aug 26, 2024 11,797 $10,000 72,334 (+16.3%) Grant
    Director
    Aug 26, 2024 11,797 $0 144,365 (+8.2%) Grant
    Director
    Aug 26, 2024 11,797 $0 97,471 (+12.1%) Grant